![]() |
Name |
Chartarlactam H
|
Molecular Formula | C25H35NO5 | |
IUPAC Name* |
(3R,4aS,7R,8R,8aS)-3,4'-dihydroxy-7'-(2-hydroxyethyl)-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1H-naphthalene-8,2'-3,6-dihydrofuro[3,2-g]isoindole]-8'-one
|
|
SMILES |
C[C@@H]1CC[C@@H]2[C@@]([C@@]13CC4=C(C=C5CN(C(=O)C5=C4O3)CCO)O)(CC[C@H](C2(C)C)O)C
|
|
InChI |
InChI=1S/C25H35NO5/c1-14-5-6-18-23(2,3)19(29)7-8-24(18,4)25(14)12-16-17(28)11-15-13-26(9-10-27)22(30)20(15)21(16)31-25/h11,14,18-19,27-29H,5-10,12-13H2,1-4H3/t14-,18+,19-,24+,25-/m1/s1
|
|
InChIKey |
JPZJNLGSNUKQJO-ZEZYSELDSA-N
|
|
Synonyms |
Chartarlactam H; CHEMBL3104967
|
|
CAS | NA | |
PubChem CID | 76313877 | |
ChEMBL ID | CHEMBL3104967 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 429.5 | ALogp: | 3.2 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 90.2 | Aromatic Rings: | 5 |
Heavy Atoms: | 31 | QED Weighted: | 0.661 |
Caco-2 Permeability: | -5 | MDCK Permeability: | 0.00000813 |
Pgp-inhibitor: | 0.039 | Pgp-substrate: | 0.965 |
Human Intestinal Absorption (HIA): | 0.151 | 20% Bioavailability (F20%): | 0.7 |
30% Bioavailability (F30%): | 0.052 |
Blood-Brain-Barrier Penetration (BBB): | 0.922 | Plasma Protein Binding (PPB): | 75.50% |
Volume Distribution (VD): | 2.887 | Fu: | 18.42% |
CYP1A2-inhibitor: | 0.233 | CYP1A2-substrate: | 0.626 |
CYP2C19-inhibitor: | 0.042 | CYP2C19-substrate: | 0.504 |
CYP2C9-inhibitor: | 0.621 | CYP2C9-substrate: | 0.743 |
CYP2D6-inhibitor: | 0.266 | CYP2D6-substrate: | 0.296 |
CYP3A4-inhibitor: | 0.151 | CYP3A4-substrate: | 0.225 |
Clearance (CL): | 9.088 | Half-life (T1/2): | 0.406 |
hERG Blockers: | 0.056 | Human Hepatotoxicity (H-HT): | 0.32 |
Drug-inuced Liver Injury (DILI): | 0.04 | AMES Toxicity: | 0.436 |
Rat Oral Acute Toxicity: | 0.883 | Maximum Recommended Daily Dose: | 0.958 |
Skin Sensitization: | 0.848 | Carcinogencity: | 0.241 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.203 |
Respiratory Toxicity: | 0.912 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002034 | ![]() |
0.828 | D04VIS | ![]() |
0.275 | ||
ENC002992 | ![]() |
0.828 | D0L2LS | ![]() |
0.261 | ||
ENC002995 | ![]() |
0.723 | D0Z1XD | ![]() |
0.259 | ||
ENC002996 | ![]() |
0.723 | D0Q6NZ | ![]() |
0.258 | ||
ENC003789 | ![]() |
0.723 | D03XOC | ![]() |
0.256 | ||
ENC003019 | ![]() |
0.676 | D0R7JT | ![]() |
0.254 | ||
ENC003552 | ![]() |
0.657 | D0PG8O | ![]() |
0.248 | ||
ENC001965 | ![]() |
0.654 | D0KR5B | ![]() |
0.248 | ||
ENC005396 | ![]() |
0.653 | D0IX6I | ![]() |
0.248 | ||
ENC003020 | ![]() |
0.653 | D0U3GL | ![]() |
0.248 |